Loading
Every dated change on the records linked to Follicular lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
R/R follicular lymphoma after ≥2 lines (accelerated)
R/R follicular lymphoma with lenalidomide and rituximab
Median investigator-assessed progression-free survival 22.
Relapsed/refractory follicular lymphoma after ≥2 lines (accelerated; full 2025 with R2)
R/R DLBCL and follicular lymphoma after ≥2 lines (conditional)
In the follicular lymphoma cohort, objective response 80.
A milestone in how this cancer is treated.
Relapsed or refractory follicular lymphoma after two or more lines, conditional
R/R follicular lymphoma after ≥2 lines (accelerated)
Relapsed or refractory follicular lymphoma after two or more lines
Relapsed/refractory follicular lymphoma
Complete response in 69.
Off-the-shelf CD20×CD3 with ~60% CR in third line.
Relapsed marginal zone lymphoma and follicular lymphoma
2-year PFS 76.
High objective and complete response rates in relapsed follicular lymphoma with durable remissions; accelerated approval in March 2021.
Axicabtagene (ZUMA-5) approved; tisagenlecleucel (ELARA) 2022; lisocabtagene 2024.
Complete response at 120 weeks 48 percent with rituximab-lenalidomide against 53 percent with rituximab-chemotherapy (p 0.
Ten-year progression-free survival 59 against 41 per cent when systemic therapy followed radiotherapy (hazard ratio 0.
Lenalidomide-rituximab matches chemo-immunotherapy first line.
Starting chemotherapy early does not lengthen life in asymptomatic, low-burden disease, and a third of people never need treatment in the first few years. The British-led trial that settled this randomised 379 patients with asymptomatic, non-bulky, advanced disease: at three years, 46 per cent of those watched had not needed treatment against 88 per cent of those given four weekly doses of rituximab and two years of maintenance (hazard ratio 0.21), with no overall survival difference. So rituximab delays the next treatment; it does not extend life, and it costs two years of visits. The GELF criteria are the usual trigger to treat: a mass of 7 cm or more, three or more nodal sites each 3 cm or more, B symptoms, splenomegaly, effusion, cytopenias or a leukaemic phase. Monitoring is clinic review and bloods every three to six months; routine scanning of a well person finds little. (NCCN Category 1 (observation for low tumour burden))
4 Gy was not non-inferior to 24 Gy for local control: five-year local progression-free rate 89.